This week in therapeutics




Licensing status

Publication and contact information



Erythropoietin (EPO); colony stimulating factor 2
receptor-b low-affinity (CSF2RB; CD131)

Mouse studies suggest an EPO mimetic could help treat burns. EPO signaling through a heteromeric receptor that combines the EPO receptor and CD131 has been shown to decrease tissue damage. In mice with partial-thickness burn wounds, ARA 290, a mimetic of the EPO b-helix region that binds the heteromeric receptor, prevented progression to full-thickness burn wounds. In this model, ARA290 decreased both inflammatory reactions and loss of microvasculature around the wound compared with vehicle. Next steps include clinical testing of the compound for burn wounds.
Araim Pharmaceuticals Inc.'s ARA290 is in Phase II testing to treat critical limb ischemia and rheumatoid arthritis (RA).

SciBX 6(7); doi:10.1038/scibx.2013.162
Published online Feb. 21, 2013

ARA290 patented by Araim Pharmaceuticals; available for licensing

Bohr, S. et al. Proc. Natl. Acad. Sci. USA;
published online Feb. 11, 2013;
Contact: Martin L. Yarmush, Massachusetts General Hospital and Shriners Hospitals for Children, Boston, Mass.